Stockscreener 앱 받기
1.8159
9.74%
-0.1341
Heartbeam Inc 주식(BEAT)의 최신 뉴스
HeartBeam’s ECG software shows promise in clinical study - Investing.com
HeartBeam announces VALID-ECG pivotal study met primary endpoint - TipRanks
Revolutionary Credit Card-Sized ECG Device Matches Hospital Grade Accuracy in Major Clinical Trial - Stock Titan
HeartBeam, AccurKardia Announce Strategic Collaboration - Diagnostic and Interventional Cardiology
HeartBeam names new auditor after Marcum resignation By Investing.com - Investing.com Nigeria
HeartBeam names new auditor after Marcum resignation - Investing.com
HeartBeam partners with AccurKardia to enhance cardiac care - Yahoo Finance
HeartBeam and AccurKardia partner on ECG tech By Investing.com - Investing.com South Africa
HeartBeam (NASDAQ: BEAT) And AccurKardia Partner To Advance Remote ECG Monitoring - Barchart.com
HeartBeam, AccurKardia Begin Cardiac Monitoring Partnership - Medical Product Outsourcing
HeartBeam and AccurKardia partner on ECG tech - Investing.com
HeartBeam and AccurKardia Announce Strategic Collaboration to Advance Cardiac Monitoring Innovation - Bluefield Daily Telegraph
Heartbeam stock touches 52-week low at $1.7 amid market challenges - Investing.com Canada
Heartbeam stock touches 52-week low at $1.7 amid market challenges By Investing.com - Investing.com South Africa
Benchmark maintains $8 target on Heartbeam stock post-Q4 report By Investing.com - Investing.com Australia
Benchmark maintains $8 target on Heartbeam stock post-Q4 report - Investing.com
HeartBeam Announces Automated Cardiac Detection Patent Granted for HeartBeam AIMIGo™ System - Business Wire
HeartBeam reports net loss of USD 4.9M in Q4 2024 - Medical Buyer
HeartBeam, Inc. (NASDAQ:BEAT) Q4 2024 Earnings Call Transcript - Insider Monkey
HeartBeam’s Earnings Call Highlights Strategic Progress - TipRanks
HeartBeam (NASDAQ: BEAT) Reports Q4 and Full-Year 2024 Financial Results, Highlights FDA Clearance and Commercial Progress - The Globe and Mail
HeartBeam Inc (BEAT) Q4 2024 Earnings Call Highlights: FDA Clearance and Strategic Moves By GuruFocus - Investing.com Canada
HeartBeam Advances Cardiac Care with FDA Clearance and New Innovations - TipRanks
Earnings call transcript: HeartBEAM Q4 2024 misses EPS forecasts - Investing.com
HeartBeam Reports Fourth Quarter and Full Year 2024 Results -March 13, 2025 at 05:31 pm EDT - Marketscreener.com
Heartbeam Inc reports results for the quarter ended December 31Earnings Summary - TradingView
HeartBeam Reports Fourth Quarter and Full Year 2024 Results - Business Wire
HeartBeam (NASDAQ: BEAT) To Present At Upcoming Investor And Industry Conferences - Barchart
HeartBeam to Participate at Upcoming Conferences in Dana Point, California, March 16-21, 2025 - The Bakersfield Californian
Meet HeartBeam Executives: Key Investment Conferences Set for California Next Month - StockTitan
HeartBeam (NASDAQ: BEAT) to Present at Upcoming Investor and Industry Conferences - The Globe and Mail
HeartBeam to Host Fourth Quarter Full Year 2024 Results Conference Call on Thursday, March 13, 2025 at 4:30 p.m. Eastern Time - The Bakersfield Californian
HeartBeam's 2024 Earnings Call: Key Updates on Cardiac Tech Commercialization Coming March 13 - Stock Titan
HeartBeam (NASDAQ: BEAT) Underwriter Exercises Option, Increasing Gross Proceeds to $11.5M - The Globe and Mail
HeartBeam closes underwriter’s over-allotment option for PO - Medical Buyer
HeartBeam Raises $11.5M: What This Capital Injection Means for Its Commercial Launch Timeline - StockTitan
HeartBeam Announces Exercise and Closing of Underwriter’s Over-Allotment Option for Public Offering of Common Stock - Business Wire
Heartbeam CFO Tim Cruickshank buys $29,999 in company stock - Investing.com India
Heartbeam director Richard Ferrari buys $50,000 in stock By Investing.com - Investing.com Australia
Heartbeam director Richard Ferrari buys $50,000 in stock - Investing.com India
Heartbeam CFO Tim Cruickshank buys $29,999 in company stock By Investing.com - Investing.com Nigeria
HeartBeam announces pricing of UPO - Medical Buyer
HeartBeam submits 510(k) application to FDA for ECG software - MSN
HeartBeam sets price for $10 million stock offering - MSN
HeartBeam prices public offering of 5.88M shares; shares down - MSN
HeartBeam Secures Major Funding: FDA-Cleared Cardiac Innovation Gets $10M Boost - StockTitan
0.07%
0.22%
자본화:
|
볼륨(24시간):